MoonLake Immunotherapeutics Cash Flow-to-Debt Ratio
MoonLake Immunotherapeutics cash flow-to-debt ratio. MoonLake Immunotherapeutics (MLTX) has a Cash Flow-to-Debt Ratio of -0.45x as of March 2026, meaning its operating cash flow of $-66.29 Million could theoretically repay 0% of its total liabilities ($146.35 Million) in one year. See MLTX free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of MoonLake Immunotherapeutics (2020–2025)
Cash flow-to-debt ratio of MoonLake Immunotherapeutics from 2020 to 2025. Historical debt coverage capacity for MoonLake Immunotherapeutics across 6 annual periods. Check MoonLake Immunotherapeutics (MLTX) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
MoonLake Immunotherapeutics Cash Flow-to-Debt Ratio by Year (2020–2025)
MoonLake Immunotherapeutics cash flow-to-debt ratio by year from 2020 to 2025. Year-by-year debt coverage analysis for MoonLake Immunotherapeutics. For the full cash flow conversion analysis, see MoonLake Immunotherapeutics (MLTX) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.63x | $-196.01 Million | $119.95 Million | ▲ +65.6% |
| 2024 | -4.75x | $-116.59 Million | $24.54 Million | ▼ -44.9% |
| 2023 | -3.28x | $-42.78 Million | $13.05 Million | ▲ +52.6% |
| 2022 | -6.92x | $-55.89 Million | $8.08 Million | ▼ -319.6% |
| 2021 | -1.65x | $-35.18 Million | $21.33 Million | ▼ -2061.4% |
| 2020 | -0.08x | $-316.69K | $4.15 Million | — |